A Study to Assess the Safety & Interaction Between GW679769, Dexamethasone, & Ondansetron When Taken by Healthy Adults
Phase 1
Completed
- Conditions
- Nausea and Vomiting, Chemotherapy-Induced
- Interventions
- Registration Number
- NCT00437229
- Lead Sponsor
- GlaxoSmithKline
- Brief Summary
GW679769 may affect liver enzymes that metabolize dexamethasone and ondansetron. This study is designed to test the safety and the extent of the GW679769 affect on dexamethasone and ondansetron levels in humans.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 37
Inclusion Criteria
- Healthy adult males or females
- Age: 18 to 55 years, inclusive
- A female subject who is non-childbearing potential or using acceptable contraceptive methods.
- Adequate organ systems function
- Able to swallow and retain oral medication
- Able to understand and comply with protocol requirements and instruction and is likely to complete the study.
Exclusion Criteria
- Cannot participation if subject has a clinically relevant abnormality, medical condition, or circumstance that makes them unsuitable for the study per the study doctor.
- History of drug or other allergy which, in the opinion of the Investigator, contraindicates participation.
- Use of an investigation drug within 28 days or 5 half-lives.
- Blood donation in excess of 500mL within 56 days prior to dosing or intends to donate within 30 days of the post-treatment follow-up visit.
- Presence of or suspected iron deficiency
- Positive stool for occult blood
- Female subject who is lactating
- Positive urine drug screen
- Positive for HIV antibody, hepatitis C antibody or hepatitis B surface antigen
- Use of tobacco-containing products within the past 12 months prior to screening
- History of drug or alcohol abuse or dependence within 6 months of screening
- History or presence of uncontrolled emesis
- Positive purified protein derivative (PPD) skin test for tuberculosis
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Subjects in Part B Casopitant (GW679769) Oral Tablets In PART B, subjects received Regimen D: oral casopitant alone (150 mg QD Day 1, 50 mg QD Days 2 and 3); Regimen E: IV dexamethasone (8 mg single-dose Day 1 only) and oral ondansetron (8 mg BID Days 1 to 3); and Regimen F: oral casopitant regimen as in Regimen D, and IV dexamethasone and oral ondansetron as in Regimen E. Subjects in Part A Casopitant (GW679769) Oral Tablets In PART A, subjects received Regimen A: oral casopitant alone (150 mg once daily \[QD\] Day 1, 50 mg QD Days 2 and 3); Regimen B: oral dexamethasone (20 mg QD Day 1 and 8 mg twice daily \[BID\] Days 2 and 3) and intravenous (IV) ondansetron (32 mg single-dose Day 1); and Regimen C: oral casopitant as in Regimen A, IV ondansetron as in Regimen B and a lower dose oral dexamethasone than in Regimen B (12 mg QD Day 1, 8 mg QD Days 2 and 3). Subjects in Part A dexamethasone In PART A, subjects received Regimen A: oral casopitant alone (150 mg once daily \[QD\] Day 1, 50 mg QD Days 2 and 3); Regimen B: oral dexamethasone (20 mg QD Day 1 and 8 mg twice daily \[BID\] Days 2 and 3) and intravenous (IV) ondansetron (32 mg single-dose Day 1); and Regimen C: oral casopitant as in Regimen A, IV ondansetron as in Regimen B and a lower dose oral dexamethasone than in Regimen B (12 mg QD Day 1, 8 mg QD Days 2 and 3). Subjects in Part A ondansetron In PART A, subjects received Regimen A: oral casopitant alone (150 mg once daily \[QD\] Day 1, 50 mg QD Days 2 and 3); Regimen B: oral dexamethasone (20 mg QD Day 1 and 8 mg twice daily \[BID\] Days 2 and 3) and intravenous (IV) ondansetron (32 mg single-dose Day 1); and Regimen C: oral casopitant as in Regimen A, IV ondansetron as in Regimen B and a lower dose oral dexamethasone than in Regimen B (12 mg QD Day 1, 8 mg QD Days 2 and 3). Subjects in Part B dexamethasone In PART B, subjects received Regimen D: oral casopitant alone (150 mg QD Day 1, 50 mg QD Days 2 and 3); Regimen E: IV dexamethasone (8 mg single-dose Day 1 only) and oral ondansetron (8 mg BID Days 1 to 3); and Regimen F: oral casopitant regimen as in Regimen D, and IV dexamethasone and oral ondansetron as in Regimen E. Subjects in Part B ondansetron In PART B, subjects received Regimen D: oral casopitant alone (150 mg QD Day 1, 50 mg QD Days 2 and 3); Regimen E: IV dexamethasone (8 mg single-dose Day 1 only) and oral ondansetron (8 mg BID Days 1 to 3); and Regimen F: oral casopitant regimen as in Regimen D, and IV dexamethasone and oral ondansetron as in Regimen E.
- Primary Outcome Measures
Name Time Method Part A: Period 1 & 2: Plasma levels of casopitant, dexamethasone, & ondansetron will be checked on Day 1, 2 and/or 3. Part B: Period 1, 2 & 3: Plasma levels of casopitant, dexamethasone, & ondansetron will be checked on Day 1, 2 and/or 3. checked on Day 1, 2 and/or 3
- Secondary Outcome Measures
Name Time Method Vitals Signs taken & Adverse Events monitored at each visit starting at Day -1. 12 lead ECGs & Serum Pepsinogen level tests at Screening & Followup. Safety is evaluated by: Clinical Lab Tests done at Screening, Day -1 & Followup.
Trial Locations
- Locations (1)
GSK Investigational Site
🇺🇸Buffalo, New York, United States